Sen-Jam Pharmaceutical (2022)
About this raise
Sen-Jam Pharmaceutical, with a valuation of $25 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1,070,000. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, and intellectual property advancement.
Investment Overview
Invested : $1,008,951
Deal Terms
Total Commitments
- Platform
- Wefunder
- Start Date
- 12/02/2021
- Close Date
- 07/31/2022
$50,000
$1,070,000
$100
Convertible Note
Early Stage
RegCF
$20,000,000
$25,000,000
20%
Company & Team
Company
- Year Founded
- 2017
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- High
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/08/2025 | Wefunder | $80,000,000 | $3,373,293 | Convertible Note | Funded | RegCF / RegD 506(c) |
| 01/06/2024 | Self Managed | - | - | Convertible Note | Funded | RegD 506(c) |
| 01/11/2023 | StartEngine | $69,979,019 | $312,093 | Equity - Common | Funded | RegCF |
| 07/31/2022 | Wefunder | $25,000,000 | $1,008,951 | Convertible Note | Funded | RegCF |
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Employee History
Founder Interview
Sen-Jam Pharmaceutical Founder Jim Iversen on Making Effective and Affordable Drugs
Prescription drug prices in the United States are painfully high. Americans pay more than twice as much as other countries for medication. This can weigh especially heavily on individuals without insurance who are struggling to make ends meet.In recognition of this problem, Sen-Jam Pharmaceutical aims to develop and sell affordable and effective oral anti-inflammation medicine. The company is working on eight products to address specific conditions, including COVID-19, opioid withdrawal, and hangovers. We reached out to co-founder and CEO Jim Iversen to learn more about the origins of the business and its plans following the raise.
Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.